Ana Lluch

Ana Lluch

UNVERIFIED PROFILE

Are you Ana Lluch?   Register this Author

Register author
Ana Lluch

Ana Lluch

Publications by authors named "Ana Lluch"

Are you Ana Lluch?   Register this Author

100Publications

3369Reads

36Profile Views

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.

Eur J Cancer 2019 Oct 4;120:54-64. Epub 2019 Sep 4.

GEICAM (Grupo GEICAM de Investigación en Cáncer de Mama), Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain; IMIM Hospital del Mar Medical Research Institute; Barcelona, Spain; Medical Oncology Department Hospital del Mar, Barcelona, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.07.003DOI Listing
October 2019

Acceleration in the DNA methylation age in breast cancer tumours from very young women.

Sci Rep 2019 Oct 18;9(1):14991. Epub 2019 Oct 18.

Biomedical Research Institute INCLIVA, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-51457-6DOI Listing
October 2019

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Oncologist 2019 May 1;24(5):603-611. Epub 2019 Feb 1.

Department of Medical Oncology and Hematology, Hospital Clínico Universitario, University of Valencia-INCLIVA Health Research Institute, CIBERONC, Valencia, Spain.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2018-0228DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516119PMC
May 2019

Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.

Curr Med Chem 2018 ;25(17):1976-1998

Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/0929867323666161216144659DOI Listing
November 2018

Breast cancer in pregnant patients: A review of the literature.

Eur J Obstet Gynecol Reprod Biol 2018 Nov 23;230:222-227. Epub 2018 Apr 23.

Medical Oncology and Hematology Unit, Health Research Institute INCLIVA, University of Valencia, The Centre of Networked Biomedical Cancer Research (CIBERONC), Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2018.04.029DOI Listing
November 2018

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

J Clin Oncol 2018 11 21;36(31):3134-3143. Epub 2018 Sep 21.

Cristina Cruz and Judith Balmaña, Vall d'Hebron Hospital; Cristina Cruz, Alba Llop-Guevara, Joaquín Arribas, Ana Vivancos, Violeta Serra, and Judith Balmaña, Vall d'Hebron Institute of Oncology; José A. Pérez Fidalgo, Ana Lluch, Joaquín Arribas, and Violeta Serra, Centro de Investigación Biomédica en Red; Joaquín Arribas, Institució Catalana de Recerca i Estudis Avançats, Barcelona; José A. Pérez Fidalgo and Ana Lluch, Hospital Clínico de Valencia, Valencia; Cristian Fernández, Carmen Kahatt, Carlos M. Galmarini, Arturo Soto-Matos, Vicente Alfaro, and Aitor Pérez de la Haza, PharmaMar, Madrid; Silvia Antolin, Complejo Universitario Hospitalario La Coruña, La Coruña; Rafael Lopez, Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Judy E. Garber, Dana Farber Cancer Institute; Nadine M. Tung, Beth Israel Deaconess Medical Center; José Baselga and Steven J. Isakoff, Massachusetts General Hospital Cancer Center, Boston, MA; Banu K. Arun, MD Anderson Cancer Center, Houston, TX; Melinda L. Telli, Stanford University School of Medicine, Stanford, CA; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; and Linda Vahdat, Weill Cornell Medicine, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209089PMC
November 2018

In Reply to Belkacemi and Tsoutsou.

Int J Radiat Oncol Biol Phys 2018 10;102(2):467-468

Peter MacCallum Cancer Centre, Melbourne, Australia; St Vincent's Hospital, University of Melbourne, Melbourne, Australia; Breast Cancer Trials Australia & New Zealand, University of Newcastle, Newcastle, Australia; International Breast Cancer Study Group, Bern, Switzerland.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016183096
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2018.06.010DOI Listing
October 2018

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

Int J Radiat Oncol Biol Phys 2018 06 6;101(2):316-324. Epub 2018 Feb 6.

International Breast Cancer Study Group, Bern, Switzerland; Peter MacCallum Cancer Centre, Melbourne, Australia; St. Vincents's Hospital, University of Melbourne, Australia; Breast Cancer Trials Australia & New Zealand, University of Newcastle, Newcastle, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.01.105DOI Listing
June 2018

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

Cell Metab 2017 Oct;26(4):633-647.e7

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmet.2017.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650077PMC
October 2017

Physical activity and breast cancer risk by pathological subtype.

Gynecol Oncol 2017 03 3;144(3):577-585. Epub 2017 Jan 3.

Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain; Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.12.014DOI Listing
March 2017

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.

Breast Cancer Res Treat 2016 11 14;160(1):69-77. Epub 2016 Sep 14.

Department of Haematology and Medical Oncology. Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, AVD/Blasco Ibánez, 17, 46010, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3980-zDOI Listing
November 2016

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.

Int J Mol Sci 2016 Aug 10;17(8). Epub 2016 Aug 10.

Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms17081298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000695PMC
August 2016

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

J Clin Oncol 2016 05 4;34(14):1584-93. Epub 2016 Jan 4.

Meritxell Bellet and Analía Azaro, Vall d'Hebron Institute of Oncology; Meritxell Bellet, Roser Ferrer, Roberto Catalán, and Analía Azaro, Vall d'Hebron University Hospital; Meritxell Bellet, Universitat Autònoma de Barcelona; Meritxell Bellet, Eva Ciruelos, Ana Lluch, Miguel Angel Climent, Gustavo Catalán, Antoni Avella, Uriel Bohn, Antonio González-Martin, Josefa Morales, and Josep Vázquez, SOLTI Group, Barcelona; Eva Ciruelos, University Hospital 12 de Octubre; Antonio González-Martin, MD Anderson Cancer Center Madrid, Madrid; Ana Lluch, Hospital Clinico Universitario de Valencia/Incliva Biomedical Research Institute; Miguel Angel Climent, Instituto Valenciano de Oncologia, Valencia; Gustavo Catalán, Hospital Son Llàtzer; Antoni Avella, Hospital Universitario Son Espases, Palma de Mallorca; Uriel Bohn, Hospital Dr Negrín de Gran Canaria, Canary Islands, Spain; Kathryn P. Gray and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray, Harvard T.H. Chan School of Public Health; Kathryn P. Gray, Karen N. Price, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Karen N. Price, Frontier Science and Technology Research Foundation; Meredith M. Regan, Harvard Medical School, Boston, MA; Agnita Rajasekaran, inVentiv Health Clinical Laboratory, Princeton, NJ; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, and International Breast Cancer Study Group, Melbourne, Victoria, Australia; and István Láng, National Institute of Oncology and International Breast Cancer Study Group, Budapest, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.2259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872316PMC
May 2016

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

J Clin Oncol 2016 05 28;34(14):1601-10. Epub 2016 Mar 28.

Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Brea

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872319PMC
May 2016

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.

PLoS One 2015 15;10(5):e0126096. Epub 2015 May 15.

Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; Cancer Epidemiology Research Group, IIS Puerta de Hierro (IDIPHIM), Majadahonda, Madrid, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0126096PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433351PMC
March 2016

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.

PLoS One 2015 15;10(6):e0129876. Epub 2015 Jun 15.

Preclinical Oncology Program, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Campus de la UAB, 08193, Bellaterra, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0129876PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467984PMC
March 2016

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.

Crit Rev Oncol Hematol 2016 Jan 11;97:96-106. Epub 2015 Aug 11.

Dept. of Hematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2015.08.011DOI Listing
January 2016

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.

J Natl Cancer Inst 2015 Dec 15;107(12):djv256. Epub 2015 Sep 15.

Oncology Program (MP, AAE, AB, MT, MG, XGA, MM, JU, SG, RRG) and Biostatistics and Bioinformatics Unit (EP), Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain; Cancer Research Program (FR, AR, JA) and Microarray Analysis Service (LN), IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Pathology Department, IIS-Fundación Jimenez Diaz, Madrid, Spain (FR); Medical Oncology Service, Hospital del Mar, Barcelona, Spain (AR, JA); Department of Oncology and Hematology, Hospital Clínico Universitario, Valencia, Spain (AL); Valencia Central University, Spain (AL); Inbiomotion, Barcelona, Spain (JJM); Sheffield Cancer Research Centre, Sheffield, UK (RC); Universitat Pompeu Fabra, Barcelona, Spain (JA); Translational Genomics, Vall d'Hebron Insitute of Oncology, Barcelona, Spain (AP); Department of Epidemiology, Harvard School of Public Health, Boston, MA (XGA); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (RRG).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/12/djv256.full.pd
Web Search
http://jnci.oxfordjournals.org/lookup/doi/10.1093/jnci/djv25
Publisher Site
http://dx.doi.org/10.1093/jnci/djv256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681582PMC
December 2015

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

J Clin Oncol 2015 Nov 28;33(32):3788-95. Epub 2015 Sep 28.

Miguel Martín, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense; Carlos Jara, Fundación Hospitalaria de Alcorcón; Noelia Martínez-Jáñez, Hospital Universitario Ramón y Cajal; César Mendiola Fernández, Hospital Universitario; Ana Isabel Ballesteros, Hospital de la Princesa; Maribel Casas, María del Carmen Cámara, and Eva Carrasco, GEICAM Headquarters, Madrid; Amparo Ruiz Simón, Instituto Valenciano de Oncología; Ana Santaballa, Hospital Universitario La Fe; Ana Lluch, Hospital Clínico Universitario de Valencia-INCLIVA-Universidad de Valencia, Valencia; Manuel Ruiz Borrego, Hospital Universitario Virgen del Rocío, Sevilla; Nuria Ribelles, Hospital Universitario Virgen de la Victoria IBIMA, Málaga; Álvaro Rodríguez-Lescure, Hospital General de Elche; Encarna Adrover, Hospital Clínico Universitario de Alicante, Alicante; Montserrat Muñoz-Mateu, Hospital Clinic i Provincial; Sonia González, Hospital Mutua de Terrassa; Mireia Margelí Vila, Hospital Universitario Germans Trias i Pujol; Agustí Barnadas, Universitat Autònoma de Barcelona, Barcelona; Manuel Ramos, Centro Oncológico de Galicia; Lourdes Calvo, Complejo Hospitalario Universitario A Coruña, A Coruã; Sonia Del Barco Berron, Instituto Catalán de Oncología, Girona; César A. Rodríguez, Hospital Universitario de Salamanca, Salamanca, Spain; Eduardo Martínez de Dueñas, Hospital Provincial de Castellón, Castellón; Raquel Andrés, Hospital Universitario Lozano Blesa, Zaragoza; Arrate Plazaola, Onkologikoa, San Sebastián; Juan de la Haba-Rodríguez, Universidad de Córdoba, Córdoba; Jose Manuel López-Vega, Hospital Universitario Marqués de Valdecilla, Santander; Pedro Sánchez-Rovira, Complejo Hospitalario de Jaén, Jaén; and José M. Baena-Cañada, Hospital Universitario Puerta del Mar, Cádiz, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.9510DOI Listing
November 2015

MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.

J Cell Biochem 2015 Sep;116(9):2061-73

INCLIVA Biomedical Research Institute, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.25162DOI Listing
September 2015

In response: Genomic profile of breast cancer.

Expert Rev Pharmacoecon Outcomes Res 2015 Jun 22;15(3):395-7. Epub 2015 Mar 22.

Medical Oncology Department, Corporació Sanitaria Parc Taulí, Sabadell, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737167.2015.1025760DOI Listing
June 2015

Involvement of Different networks in mammary gland involution after the pregnancy/lactation cycle: Implications in breast cancer.

IUBMB Life 2015 Apr 21;67(4):227-38. Epub 2015 Apr 21.

Instituto INCLIVA, Facultad de Medicina/Hospital Clínico, Universidad de Valencia, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/iub.1365DOI Listing
April 2015

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.

Expert Rev Pharmacoecon Outcomes Res 2014 Dec 12;14(6):889-99. Epub 2014 Sep 12.

Medical Oncology Department, Corporació Sanitaria Parc Taulí, Sabadell, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737167.2014.957185DOI Listing
December 2014

Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk.

Eur J Cancer 2014 Dec 31;50(18):3168-77. Epub 2014 Oct 31.

Department of Hematology and Medical Oncology, Health Research Institute-INCLIVA, Valencia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.09.017DOI Listing
December 2014

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

Eur J Cancer 2014 Oct 12;50(15):2725-34. Epub 2014 Aug 12.

Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.07.004DOI Listing
October 2014

Emerging EGFR antagonists for breast cancer.

Expert Opin Emerg Drugs 2014 Jun 15;19(2):165-81. Epub 2014 May 15.

Hospital Clinico Universitario, INCLIVA Biomedical Research Institute, Department of Oncology and Hematology , Valencia , Spain +0034 963987659 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2014.903919DOI Listing
June 2014

Concordance of genomic alterations between primary and recurrent breast cancer.

Mol Cancer Ther 2014 May 7;13(5):1382-9. Epub 2014 Mar 7.

Authors' Affiliations: Departments of Investigational Cancer Therapeutics, Surgical Oncology, Bioinformatics and Computational Biology, Pathology, Systems Biology, and Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Foundation Medicine, Cambridge, Massachusetts; Albany Medical College, Albany, New York; Fundacion para la Investigacion; Departments of Hematology-Oncology and Pathology, Hospital Clinico Universitario de Valencia; and INCLIVA Biomedical Research Institute, Valencia, Spain.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-13
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-13-0482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348062PMC
May 2014

Trastuzumab in small tumours and in elderly women.

Cancer Treat Rev 2014 Feb 6;40(1):41-7. Epub 2013 May 6.

Medical Oncology Service, Hospital del Mar, IMIM (Hospital del Mar Research Institute), Pompeu Fabra University, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2013.04.002DOI Listing
February 2014

Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.

Crit Rev Oncol Hematol 2014 Jan 21;89(1):62-72. Epub 2013 Aug 21.

Centro Integral Oncológico Clara Campal, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.08.001DOI Listing
January 2014

Zoledronic acid in the treatment of metastatic breast cancer.

Anticancer Drugs 2014 Jan;25(1):1-7

aDepartment of Medical Oncology and Hematology, Institute of Health Research INCLIVA, Hospital Clínico Universitario, Valencia bDepartment of Medical Oncology, C. H. U., Santiago de Compostela cDepartment of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla dDepartment of Medical Oncology, Hospital General Universitario, Alicante, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000020DOI Listing
January 2014

High stability of microRNAs in tissue samples of compromised quality.

Virchows Arch 2013 Dec 3;463(6):765-74. Epub 2013 Oct 3.

Biobank, INCLIVA Biomedical Research Institute, Avenida Blasco Ibáñez, 17, 46010, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-013-1485-2DOI Listing
December 2013

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.

Breast 2013 Oct 25;22(5):974-9. Epub 2013 Jun 25.

Department of Oncology and Hematology, Research Institute INCLIVA, Hospital Clinico Universitario Valencia (HCUV), Avda Blasco Ibañez 17, 46010 Valencia, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.05.014DOI Listing
October 2013

Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Mol Cell Biochem 2013 Jul 6;379(1-2):181-90. Epub 2013 Apr 6.

Institute of Health Research INCLIVA, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11010-013-1640-8DOI Listing
July 2013

High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients.

Oncologist 2012 14;17(6):766-74. Epub 2012 May 14.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2011-0377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380875PMC
November 2012

Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

Cancer Treat Rev 2012 Oct 16;38(6):698-707. Epub 2011 Dec 16.

Fundación Investigación del Hospital Clínico Universitario de Valencia/INCLIVA, Av. Blasco Ibáñez 17, 46010 Valencia, Spain.

View Article

Download full-text PDF

Source
http://xa.yimg.com/kq/groups/24808814/238304805/name/Molecul
Web Search
http://dx.doi.org/10.1016/j.ctrv.2011.11.005DOI Listing
October 2012

The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population.

Breast Cancer Res Treat 2012 Jun;133(2):769-78

Fundación Investigación Hospital Clínico Universitario/INCLIVA, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-012-1980-1DOI Listing
June 2012

Evolution of tumour biology upon progression. Do we know our enemy?

Authors:
Ana Lluch Ana Bosch

Clin Transl Oncol 2012 Jun;14(6):399-400

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-012-0816-0DOI Listing
June 2012

Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.

Oncologist 2011 28;16(7):956-65. Epub 2011 Jun 28.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2010-0409DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228141PMC
January 2012

Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?

Breast 2011 Dec 3;20(6):548-54. Epub 2011 Aug 3.

Department of Medical Oncology, Hospital Clinico Universitario, Avda Blasco Ibanez s/n, 46018 INCLIVA, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2011.06.005DOI Listing
December 2011

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

Mol Cancer Ther 2011 Jun 13;10(6):1093-101. Epub 2011 Apr 13.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-1089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112276PMC
June 2011